Last reviewed · How we verify
Azithromcyin
At a glance
| Generic name | Azithromcyin |
|---|---|
| Sponsor | University of Santiago de Compostela |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Short-term Bactericidal Effect of Contezolid in MAC-PD (PHASE4)
- Non-Surgical Treatment of Peri-implantitis with Systemic Azithromycin or Placebo (PHASE4)
- Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease (PHASE2)
- Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azithromcyin CI brief — competitive landscape report
- Azithromcyin updates RSS · CI watch RSS
- University of Santiago de Compostela portfolio CI